AI Healthcare Stocks: Pfizer and Two Others to Watch Now

From where I sit in lower Manhattan, the chatter on the trading floor often swings between two extremes: unbridled hype and cold, hard panic. Right now, a lot of that panic is swirling around the staggering debt piling up for companies building the foundational chips and data centers for artificial intelligence. It’s a legitimate concern, one that sends a clear signal. When financing for the flashy infrastructure gets shaky, smart money starts looking for the substance. It looks for where AI is solving urgent, real-world problems today, not just promising a distant tomorrow.

That search leads directly to healthcare. This is not about chatbots or image generators. This is about algorithms that can parse biological data to discover new drugs, or interpret brain waves at a patient’s bedside, or create a dynamic model of a beating heart. The financial strain in the tech infrastructure sector makes these grounded applications look less like science fiction and more like essential medicine. For investors, it shifts the focus from speculative bets on builders to analytical bets on users. Companies that are wiring AI directly into the fabric of saving lives and reducing costs are commanding a new level of attention.

Consider Pfizer. With a market cap hovering around $173 billion, it’s a titan. But its relevance here isn’t just about size. It’s about a deliberate, operational shift. The company is embedding machine learning across its entire chain, from initial drug discovery to clinical trials and commercial sales. Management has stated this push has already tripled salesforce productivity in some international markets and shortened critical reporting timelines. For a firm that generated over $62 billion from its biopharmaceuticals business last year, even marginal efficiency gains from AI are measured in the hundreds of millions. The real question for an investor isn’t if Pfizer is using AI. It’s which AI-driven pipeline shift will materially reshape its earnings power first. Will a machine-learning-prioritized cancer therapy beat expectations? Will an AI-optimized trial for a neurological drug save two years in development? The answers to those specific questions will matter far more than any generic corporate mention of “AI initiatives.”

Then there are the specialists, where AI is the entire product. CeriBell, valued at about $1.1 billion, makes this tangible. Its Ceribell system is a portable EEG device that uses a proprietary algorithm called Clarity to detect seizure activity in real time. This isn’t analysis in a lab. This is at the bedside in a chaotic ICU. The company’s story, and its potential $102 million in revenue, is tied directly to a concrete trend: hospitals are formalizing seizure management protocols for patients who have suffered strokes or cardiac arrest. This drives mandated, recurring use of EEG monitoring. CeriBell’s challenge is turning that clinical utility into sustainable profitability. The investment thesis rests on a simple metric: can the growth of its high-margin recurring revenue from these hospital protocols outpace the costs of scaling? It’s a pressure point every analyst is watching.

HeartFlow presents another precise application. The company takes a standard coronary CT scan and uses AI to build a personalized, 3D model of a patient’s arteries, simulating blood flow. This helps cardiologists decide who truly needs an invasive stent or bypass. With a market cap of $4.8 billion and revenues near $212 million, HeartFlow’s near-term catalyst is administrative, not just technological. In 2026, its Plaque Analysis is slated to receive a Category I CPT code from Medicare, which defines a reimbursement rate. Commercial insurers are already on board for over half of U.S. patients. This transition from an innovative tool to a routinely billed procedure is a fundamental financial inflection point. The quiet assumption baked into its valuation is a significant rise in case volumes. If adoption accelerates as reimbursement solidifies, the model works. If volumes plateau, questions will arise.

These three companies are just a snapshot. A deeper screen would reveal dozens more with similarly compelling, specific stories. The common thread is that their AI application is not a side project. For Pfizer, it’s a lever for R&D efficiency at scale. For CeriBell, it’s the core diagnostic product in a growing clinical niche. For HeartFlow, it’s the engine for turning imaging data into reimbursable insight. This is what substance looks like.

While the market fixates on the debt burdens of AI infrastructure firms, the real durability may lie in these vertical applications. The narrative is moving from building the brain to applying its intelligence. In healthcare, the problems are vast, the costs are high, and the need for smarter solutions is perpetual. That creates a different kind of investment landscape—one driven less by momentum and more by measurable impact on a hospital’s bottom line or a drugmaker’s pipeline. It’s a more grounded but perhaps more consequential place to look.

• Companies are embedding AI into healthcare solutions.
• Focus is shifting to real-world applications of AI.
• Pfizer is tripling productivity through machine learning.
• CeriBell is addressing urgent EEG monitoring needs.
• HeartFlow is revolutionizing coronary artery modeling.
• Healthcare AI investments appear more sustainable.